CAR-T
-
Infections, immune recovery and long-term safety
Remission from autoimmune disease does not mean immediate recovery of every protective immune function.
-
Acute toxicity: distinguish the syndromes
Fever, organ deterioration and neurologic symptoms need assessment—not an assumption that treatment is “working.”
-
The treatment journey: more than an infusion
From assessment through manufacturing, conditioning, recovery and shared follow-up.
-
Who should be referred for a CAR-T research assessment?
A structured discussion framework—not an eligibility score or a prescription.
-
Children, adolescents and reproductive questions
Potential lifetime benefit makes careful evidence and long-term follow-up more—not less—important.
-
Vasculitis, overlap syndromes and the limits of extrapolation
Keep rare human signals visible without filling evidence gaps with assumptions.
-
Sjögren’s disease: strong rationale, limited direct clinical evidence
Separate systemic immune activity, glandular reserve and lymphoma-associated observations.
-
Rheumatoid arthritis: the 2026 COMPARE signal
An important new human result — not a reason to bypass established RA care.
-
Inflammatory myopathies: phenotype before escalation
Dermatomyositis, antisynthetase disease and necrotizing myopathy should not be treated as one evidence category.
-
Systemic sclerosis: beyond suppressing inflammation
A promising opportunity to examine immune control, fibrosis and repair separately.